A Phase 1b Open-Label Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFalpha Antibody, in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Golimumab (Primary)
- Indications Ulcerative colitis
- Focus Pharmacokinetics
- Acronyms PURSUIT-PEDS-PK
- Sponsors Janssen Research & Development
- 24 Sep 2019 This trial was completed in Germany, according to European Clinical Trials Database.
- 16 May 2018 Planned End Date changed from 8 Aug 2023 to 8 Jan 2024.
- 23 Dec 2017 trial has been completed in Denmark